Race Oncology (ASX:RAC) Activates First Australian Clinical Site for RC220 Trial
Clinical Trial Initiation
Race Oncology has activated the Southside Cancer Care Centre in Miranda, NSW, to begin enrolling patients in its Phase 1 trial of RC220 combined with doxorubicin for advanced solid tumours. The open-label trial will be conducted across multiple sites in Australia, Hong Kong, and South Korea, using ascending doses of RC220 in up to 33 patients to determine safety, tolerability, and pharmacokinetics.
Study Overview
The Phase 1 trial aims to identify the maximum tolerated combined dose of RC220 and doxorubicin, and assess effects on clinical biomarkers including m6A RNA. An interim analysis will determine the optimal dosage for an additional 20 patients, focusing on safety, tolerability, and preliminary cardioprotective and anticancer efficacy signals. The trial employs a Bayesian design for increased flexibility and speed.
Executive Comments
CEO Dr Daniel Tillett stated, “I am proud of the hard work and dedication from the Race clinical team, George Clinical and CCF in reaching this point. I look forward to soon treating the first patient with RC220 and beginning the process of advancing RC220 as a potential new treatment able to improve cancer therapy while protecting patients from the serious side effects of cancer treatment.”
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
